Related Experiment Video
Updated: Oct 5, 2025
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Clinical development of an anti-GPC-1 antibody for the treatment of cancer
Saikat Ghosh1, Pie Huda1, Nicholas Fletcher1
1Centre for Advanced Imaging (CAI)-Australian Institute for Bioengineering and Nanotechnology (AIBN), ARC Training Centre for Innovation in Biomedical Imaging Technologies, the University of Queensland, Brisbane, Australia.
Introduction:
Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential. Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically.
Areas Covered:
This review addresses GPC-1 targeting antibodies for cancer therapy, in preclinical and clinical development. Current and emerging development of different anti-GPC-1 antibody formats based on mechanism of action and application are also discussed.
Expert Opinion:
Clinical development of novel anti-GPC-1 antibody-based formats is still in its early days. Using the patented anti-GPC-1 Miltuximab® as a case study, we have made an attempt to illustrate a pathway for preclinical to clinical translation, which could be useful for newer GPC-1 targeting immunotherapy agents.
